当前位置: 首页 >> 检索结果
4121. Clinically suspect arthralgia patients with a low educational attainment have an increased risk of developing inflammatory arthritis.
作者: Sarah J H Khidir.;Anna M P Boeren.;Annelies Boonen.;Pascal H P de Jong.;Elise van Mulligen.;Annette H M van der Helm-van Mil.
来源: Rheumatology (Oxford). 2023年62卷5期1944-1949页
Cross-sectional studies have shown that rheumatoid arthritis is more prevalent among people with a lower educational attainment. No longitudinal data are present on educational attainment in the at-risk phase of clinically suspect arthralgia (CSA). We therefore analysed the association between educational attainment and progression from CSA to inflammatory arthritis (IA), and performed mediation analysis with subclinical joint inflammation to elucidate pathways of this association.
4122. Coping strategies, emotional distress and perceived disease severity in a cohort of patients with rheumatoid arthritis: a mediation analysis.
作者: Sarah Tosato.;Chiara Bonetto.;Alice Zanini.;Ilaria Montanari.;Anna Piccinelli.;Riccardo Bixio.;Maurizio Rossini.;Giulio Pacenza.;Doriana Cristofalo.;Elena Fracassi.;Antonio Carletto.
来源: Rheumatology (Oxford). 2023年62卷3期1078-1086页
Few data are available on the role of emotional distress as a possible mediator of the relationship between coping strategies and the Patient Global Assessment (PGA). This study aims to investigate, in a large cohort of patients affected by RA, the relationship between specific copying strategies and PGA, and the role of emotional distress as a mediator.
4123. Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study.
作者: Vasiliki-Kalliopi Bournia.;George E Fragoulis.;Panagiota Mitrou.;Konstantinos Mathioudakis.;Anastasios Tsolakidis.;George Konstantonis.;Ioulia Tseti.;Georgia Vourli.;Maria G Tektonidou.;Dimitrios Paraskevis.;Petros P Sfikakis.
来源: Rheumatology (Oxford). 2023年62卷3期1047-1056页
To investigate coronavirus disease 2019 (COVID-19)-associated risk of hospitalization and death in RA, AS, PsA, SLE and SSc in comparison with the general population during the first year of the pandemic, and compare their overall mortality with 2019.
4124. Ultrasonography in the prediction of gout flares: a 12-month prospective observational study.
作者: Edoardo Cipolletta.;Abhishek Abhishek.;Jacopo Di Battista.;Walter Grassi.;Emilio Filippucci.
来源: Rheumatology (Oxford). 2023年62卷3期1108-1116页
To evaluate whether US findings indicating MSU deposits and US-detected inflammation (i.e. power Doppler signal) predict gout flares over 12 months.
4125. Differences in symptom experience among patients with systemic sclerosis: a cluster analytic approach to identifying subgroups.
作者: Susan L Murphy.;Yen T Chen.;Yvonne C Lee.;Mary Carns.;Kathleen Aren.;Benjamin Korman.;Monique Hinchcliff.;John Varga.
来源: Rheumatology (Oxford). 2023年62卷SI期SI64-SI73页
Symptoms of people who have SSc are heterogeneous and difficult to address clinically. Because diverse symptoms often co-occur and may share common underlying mechanisms, identifying symptoms that cluster together may better target treatment approaches. We sought to identify and characterize patient subgroups based on symptom experience.
4126. Utility of repeat extractable nuclear antigen antibody testing: a retrospective audit.
作者: Ai Li Yeo.;Michelle Leech.;Samar Ojaimi.;Eric Morand.
来源: Rheumatology (Oxford). 2023年62卷3期1248-1253页
Autoantibodies to ENA are frequently ordered during the workup of suspected autoimmune connective tissue diseases. There are no current guidelines for repeat test ordering. The objective of this study was to assess the utility of repeat ENA testing after an initial negative result.
4127. Fibroblast expression of CD248 may contribute to exacerbation of microvascular damage during systemic sclerosis.
作者: Paola Cipriani.;Piero Ruscitti.;Ilenia Di Cola.;Marta Vomero.;Franca Abbruzzese.;Elena Di Nino.;Rebecca Ross.;Francesco Del Galdo.;Roberto Giacomelli.
来源: Rheumatology (Oxford). 2023年62卷3期1317-1325页
CD248 is a glycoprotein, highly expressed on pericytes and fibroblasts (FBs), that is implicated in the fibrotic process. During angiogenesis, CD248 can promote vessel regression, binding multimerin-2 (MMRN-2). Thus, we investigated the expression of MMRN-2 in systemic sclerosis (SSc)-skin and of CD248 in isolated SSc-FBs. The anti-angiogenic property of CD248+ SSc-FBs was evaluated by co-culturing these cells with healthy control endothelial cells (HC-ECs). The apoptotic effect of CD248 on HC-ECs was evaluated. Finally, the ability of CD248 to prevent activation of VEGF receptor 2 (VEGFR2) was assessed.
4129. Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis.
作者: Baozhen Huang.;Xinning Wang.;Yanlin Niu.;Yuchuan Ding.;Xiaolei Wang.;Qingqing Tan.;Yucong Li.;Yuan Liu.;Ying Chi.;Yuan Wang.;Zhixuan Zhou.;Jianguo Li.
来源: Rheumatology (Oxford). 2023年62卷3期1227-1237页
To evaluate the use of Janus kinase inhibitor (JAKi) in treating JDM and develop cytokine biomarkers of active disease.
4130. Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model.
作者: Alexandru Garaiman.;Klaus Steigmiller.;Catherine Gebhard.;Carina Mihai.;Rucsandra Dobrota.;Cosimo Bruni.;Marco Matucci-Cerinic.;Joerg Henes.;Jeska de Vries-Bouwstra.;Vanessa Smith.;Andrea Doria.;Yannick Allanore.;Lorenzo Dagna.;Branimir Anić.;Carlomaurizio Montecucco.;Otylia Kowal-Bielecka.;Mickael Martin.;Yoshiya Tanaka.;Anna-Maria Hoffmann-Vold.;Ulrike Held.;Oliver Distler.;Mike Oliver Becker.; .
来源: Rheumatology (Oxford). 2023年62卷SI期SI91-SI100页
To develop and validate the prognostic prediction model DU-VASC to assist the clinicians in decision-making regarding the use of platelet inhibitors (PIs) for the management of digital ulcers in patients with systemic sclerosis. Secondly, to assess the incremental value of PIs as predictor.
4134. Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells.
作者: Eloisa Romano.;Irene Rosa.;Bianca Saveria Fioretto.;Dilia Giuggioli.;Mirko Manetti.;Marco Matucci-Cerinic.
来源: Rheumatology (Oxford). 2023年62卷SI期SI125-SI137页
In SSc, angiogenesis impairment advances in parallel with the development of fibrosis orchestrated by myofibroblasts originating from different sources, including endothelial-to-mesenchymal transition (EndoMT). Soluble guanylate cyclase (sGC) stimulation has shown antifibrotic effects in SSc skin fibroblasts and mouse models. Here, we investigated the effects of pharmacological sGC stimulation on impaired angiogenesis and myofibroblast-like features of SSc dermal microvascular endothelial cells (SSc-MVECs).
4135. Prevalence of non-coeliac gluten sensitivity and assessment of the response to gluten-free diet in a cohort of patients with fibromyalgia.
作者: Miriam Almirall.;Francesc Casellas.;Joan Dot.;Inés de Torres.;Hegoi Segurola.;Sara Marsal.
来源: Rheumatology (Oxford). 2023年62卷3期1069-1077页
To establish the prevalence of non-coeliac gluten sensitivity (NCGS) in a cohort of fibromyalgia patients and to evaluate their clinical response to a six-week gluten-free diet (GFD), the improvement in their symptoms, the percentage of diet responders who did not fulfil the diagnostic criteria for NCGS and the baseline characteristics that were associated with diet response and diagnostic criteria fulfilment.
4136. Reduced Cathepsin L expression and secretion into the extracellular milieu contribute to lung fibrosis in systemic sclerosis.
作者: Joe E Mouawad.;Shailza Sharma.;Ludivine Renaud.;Joseph M Pilewski.;Satish N Nadig.;Carol Feghali-Bostwick.
来源: Rheumatology (Oxford). 2023年62卷3期1306-1316页
Lung fibrosis is the leading cause of death in SSc, with no cure currently available. Antifibrotic Endostatin (ES) production does not reach therapeutic levels in SSc patients, suggesting a deficit in its release from Collagen XVIII by the main cleavage enzyme, Cathepsin L (CTSL). Thus, elucidating a potential deficit in CTSL expression and activity unravels an underlying molecular cause for SSc-driven lung fibrosis.
4137. Predictors and prognostic stratification for lupus low disease activity state: results from a prospective clinical trial.
作者: Kai Zhang.;Yuan An.;Peng Zhao.;Bo Huang.;Yifan Wang.;Xingyu Zhou.;Gong Cheng.;Xiaoyan Xing.;Naidi Wang.;Ruiling Feng.;Siyue Yu.;Min Li.;Jing He.;Zhanguo Li.
来源: Rheumatology (Oxford). 2023年62卷3期1153-1161页
To identify predictors for lupus low disease activity state (LLDAS), early-achieved LLDAS and long-term disease activity, and to refine a prognostic stratification tool for use in active SLE patients.
4138. A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's.
作者: Ariane L Herrick.;Rohit Batta.;Kamilla Overbeck.;Johan Raud.;Joanne Manning.;Andrea Murray.;Graham Dinsdale.;Göran Tornling.
来源: Rheumatology (Oxford). 2023年62卷2期824-828页
Our main aim was to investigate the effect of a single oral dose of C21, a selective angiotensin II type 2 receptor agonist, on cold-induced vasoconstriction in SSc-related RP.
|